Skip to main
ARDT
ARDT logo

ARDT Stock Forecast & Price Target

ARDT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 36%
Hold 27%
Sell 9%
Strong Sell 0%

Bulls say

Ardent Health Inc. demonstrated a strong financial performance with an EBITDA of $143 million, representing a 46% year-over-year increase, alongside an improved margin of 9.1%, up by 240 basis points compared to the previous year. The company experienced a notable growth in inpatient admissions, which rose 5.8% year-over-year, significantly outpacing the peer average of 1.7%, indicating robust demand in its service offerings. Additionally, improvements in contract labor costs and strategic investments in capital expenditures suggest a focused approach towards efficiency and growth in the healthcare market.

Bears say

The negative outlook on Ardent Health Inc. is primarily driven by a significant EBITDA miss of $143 million, reflecting a 2% shortfall against estimates, and underlying performance deterioration exacerbated by one-time gains in the previous quarter. Additionally, a substantial revenue adjustment of $43 million due to the transition to the Kodiak revenue cycle management platform has led to a more conservative stance regarding accounts receivable collectability, suggesting minimal to negative EBITDA growth for 2026. The downward revisions of EBITDA estimates for 2025 and 2026, alongside increasing claims denials and professional fee challenges, indicate persistent financial headwinds that could severely impact cash flow generation moving forward.

ARDT has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardent Health Partners LLC (ARDT) Forecast

Analysts have given ARDT a Buy based on their latest research and market trends.

According to 11 analysts, ARDT has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardent Health Partners LLC (ARDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.